A 12-week randomized, double-blind, four-arm parallel-group, comparative study was conducted in patients with essential hypertension to evaluate the antihypertensive effect and safety of combination therapy with olmesartan medoxomil (OLM, an angiotensin-receptor blocker) 20 mg plus azelnidipine (AZL, a long-acting dihydropyridine calcium channel blocker (20) and AZL (16) monotherapy groups (À12.1/À6.9 and À12.0/À6.9 mm Hg). The proportion of patients achieving the SeBP goal (o130/85 mm Hg for normal BP or o140/90 mm Hg for high-normal BP) was significantly higher in the O/A (20/16) combination group than in the monotherapy groups. The incidence of adverse events was similar in the O/A combination groups and the monotherapy groups. These results showed that combination therapy with O/A was well tolerated and exerted a stronger antihypertensive effect compared with monotherapy with OLM or AZL in patients with essential hypertension.
INTRODUCTION
Hypertension is an important risk factor for cardiovascular and cerebrovascular diseases. 1 The goal of antihypertensive treatment is to prevent cerebrovascular and cardiovascular diseases by appropriate blood pressure (BP) control. In many countries, however, BP is not adequately controlled in more than 50% of patients. [2] [3] [4] Generally, multiple factors are considered responsible for hypertension; therefore, in many cases, two or more drugs with different mechanisms of action are required to achieve BP control. 2, 4 The guidelines for the management of hypertension in Japan, the United States and Europe recommend considering a combination of two drugs at the beginning of treatment in patients with high-risk hypertension or grades II-III hypertension. 2, 4, 5 An angiotensin-receptor blocker (ARB) plus a calcium channel blocker (CCB) is one of the antihypertensive combinations recommended in the JSH2009. 5 This ARB/CCB combination therapy is reported to be highly effective compared with high-dose monotherapy. 6, 7 Previous studies suggested that in addition to the antihypertensive effect, ARBs might directly prevent organ damage, for example, by protecting the heart through regression of left ventricular hypertrophy, or by protecting the kidney through decreasing proteinuria. 8, 9 Similarly, dihydropyridine CCBs might have organ-protective effects (that is, regression of left ventricular hypertrophy or inhibition of the progression of atherosclerosis). 10, 11 The ACCOMPLISH study demonstrated that treatment with an angiotensin-converting enzyme inhibitor plus a CCB was associated with a 20% reduction in cardiovascular morbidity and mortality in high-risk patients, relative to angiotensin-converting enzyme inhibitor/diuretic therapy. 12 These findings suggest that the combination of a renin-angiotensin system inhibitor and a CCB may be effective in preventing cardiovascular events. As stated above, the combination of a renin-angiotensin system inhibitor, such as an ARB, and a CCB exerts an excellent antihypertensive effect and may inhibit cardiovascular events. According to a survey of prescriptions for hypertension in Japan, ARB plus CCB is the most common combination among all prescriptions. 13 We investigated the antihypertensive effect of combination therapy (O/A) with olmesartan medoxomil (OLM), an ARB, and azelnidipine (AZL), a long-acting dihydropyridine CCB. We evaluated the efficacy and safety of 12-week O/A combination therapy compared with OLM or AZL monotherapy in Japanese patients with essential hypertension. As 24-h BP control has become increasingly important in recent years, the antihypertensive effect of O/A was evaluated by ambulatory BP monitoring (ABPM) in addition to conventional cuff BP measurement.
METHODS Subjects
Male and female outpatients with essential hypertension who met the following criteria were enrolled: age X20 years; mean of the seated BP (SeBP) in the clinic at the last two visits during the run-in period: systolic BP (SBP)X140 to o180 mm Hg and diastolic BP (DBP)X90 to o110 mm Hg; 24-h ambulatory BP in the run-in period: SBPX135 and DBPX80 mm Hg. Main exclusion criteria were as follows: secondary or malignant hypertension, myocardial infarction or cerebrovascular disorder within 3 months before informed consent, unstable angina pectoris, severe heart failure (NYHA class III or IV), serious arrhythmia (grade II or III atrioventricular block), requiring treatment for malignant tumors, bradycardia, hepatic function disorder, renal function disorder or poorly controlled diabetes.
This study was conducted according to the principles of the Declaration of Helsinki and Good Clinical Practices. This study was approved by the Institutional Review Board of each study site before implementation. Each participant gave written informed consent for this study before participation. This study is registered as ID number JapicCTI-060286 at the Japan Pharmaceutical Information Center.
Study design
The study design is shown in Figure 1 . This was a multicenter, randomized, double-blind, four-arm parallel-group, comparative study consisting of a 4-week placebo run-in period and a 12-week double-blind treatment period. Patients visited the study site at the beginning, at week 3, and at the end of the run-in period; at weeks 2, 4, 6, 8, 10 and 12 of the treatment period; and the day after completion of treatment. Patients were randomly assigned to the following four treatments: AZL 16 mg (AZL (16) 
Study assessments
Vital signs and physical findings were recorded at every visit. SeBP was measured by auscultation using a mercury sphygmomanometer. BP was measured three times with 1 or 2-min intervals at trough (24 ± 3 h post-dose); the mean value of these three measurements was used for analysis. Twentyfour-hour ABPM was performed during the run-in period and on week 12 during the treatment period. Using a validated ABPM device (TM-2431, A&D, Tokyo, Japan), SBP, DBP and pulse rate (PR) were continuously measured and recorded for more than 25 h in 30-min intervals. Laboratory examinations (hematology, blood biochemistry and urinalysis) were performed during the run-in period and at completion of the treatment period.
Study end point
Primary end point was the change from baseline in SeBP (SBP and DBP) at study end. SeBP during the run-in period was defined as the mean of BP at the last two visits, and SeBP at study end was defined as the mean of BP at the last two visits during the treatment period. Secondary end points were as follows: proportion of patients achieving the SeBP goal (SBP/DBPo130/85 mm Hg, criteria for normal BP by cuff measurement) at study end, the change from baseline in the clinic seated PR at study end and the change from baseline in 24-h ambulatory BP at study end. In addition, the following values at study end were defined as post hoc end points: proportion of patients achieving the SeBP goal (SBP/DBPo140/90 mm Hg, criteria for high-normal BP by cuff measurement); proportion of patients achieving SBP/DBPo140/90 mm Hg classified by age (o65 years, X65 years); and responder rate (the proportion of patients with clinic SBP/DBPo140/90 mm Hg; or with either clinic SBP decreased 420 mm Hg or clinic DBP decreased 410 mm Hg, and mean BP (that is, (SBP+2DBP)/3) decreased 413 mm Hg). The safety end points were defined as the incidence of adverse events (AEs).
Statistical analysis
A sample size of 180 patients per group would have 90% power to detect all the differences of 6 and 3 mm Hg in the primary SBP and DBP end points between the O/A (20/16) group and the monotherapy (AZL (16) or OLM (20) ) group assuming that the common s.d. would be 11 and 8 mm Hg, respectively, and the correlation coefficient between SBP and DBP would be 0.7 using 2000 simulations of a t-test with a 0.05 two-sided significance level. The number of patients was determined to be 190 for each group in consideration of possible withdrawals.
Patients included for the primary efficacy analysis were the full analysis set. The safety analysis set was patients who received the study drug at least once during the treatment period.
In the treatment comparison for the SeBP (primary end point), P-values were calculated by an analysis of covariance with SeBP value at baseline, gender and weight as covariates. The adjusted mean value for each treatment group and the 95% confidence interval were also calculated. In the comparison for the proportion of patients achieving the SeBP goal, logistic regression was performed with the severity of hypertension at baseline, gender and weight as covariates. Subsequently, adjusted odds ratios, P-values between treatment groups and the 95% confidence intervals were calculated. Subgroup (gender, weight (o67.5 kg, X67.5 kg), age (o65 years, X65 years), severity of hypertension (grade I or II) and complication (hyperlipidemia, hyperuricemia and diabetes)) analyses of primary end point were conducted. All statistical analyses were performed using SAS version 8.02 (SAS Institute, Cary, NC, USA).
RESULTS

Study population
Of 1206 patients who gave consent, 1202 participated in the run-in period of the study. Subsequently, 867 out of 1202 patients were randomized and assigned to one of the four treatments (AZL (16) Efficacy and safety of olmesartan plus azelnidipine T Ogihara et al Three hundred and thirty five patients were dropped in the run-in period, mainly due to failure to meet the eligibility criteria (n¼226), withdrawal of consent (n¼54) and occurrence of AEs (n¼14). Of the 867 patients advanced to the treatment period, 862 patients were included in the full analysis set, and 866 patients were included in the safety analysis set. Five patients were excluded from the full analysis set (AZL (16), n¼1; OLM (20), n¼2; O/A (10/8), n¼1; O/A (20/16), n¼1) mainly due to lack of SeBP data after randomization. The baseline characteristics are shown in Table 1 . There were no major differences in age, gender, BP, weight, body mass index, complications and severity of hypertension among all groups.
Efficacy
The change from baseline in SeBP at study end in each group is shown in Figure 2a . These changes were À15.0/À9.4 mm Hg (SBP/DBP) in the AZL (16) Figure 3 . In all treatment groups, both SBP and DBP decreased from the start of treatment to week 2. Particularly, SBP and DBP in the combination groups decreased by more than 15 and 10 mm Hg at week 2, respectively. A stable antihypertensive effect was observed throughout the study period, and O/A (20/16) combination therapy showed the greatest effect.
The proportion of patients achieving the SeBP goal (SBP/ DBPo130/85 mm Hg or o140/90 mm Hg) at study end is shown in Figure 4 . The proportion of patients achieving the SeBP goal in the O/A (20/16) combination group was significantly higher than in the monotherapy groups (Pp0.0011). The responder rates were 53.2% in the AZL (16) Seated BP reduction and BP goal achievement at the study end was analyzed for each subgroup. In terms of gender and weight, the antihypertensive effect seemed greater in females and in lower bodyweight patients, but this was considered to have no clinically significant influence. There were also no clinically significant differences among other subgroups in any treatment group. Thus, O/A combination showed a strong antihypertensive effect regardless of patient background factors (gender, weight, age, severity of hypertension and complication).
Safety
The number of patients who experienced AEs is summarized in Table 2 Efficacy and safety of olmesartan plus azelnidipine T Ogihara et al related AEs were dizziness, headache, elevated alanine aminotransferase, elevated aspartate aminotransferase , elevated C-reactive protein and elevated g-glutamyl transferase. In the elderly (X65 years of age), the incidence of drug-related AEs was 18.5% (10/54 patients) in the AZL (16) Efficacy and safety of olmesartan plus azelnidipine T Ogihara et al These doses were selected as low-dose combination because they are the starting doses according to the package inserts in Japan. The reduction in SeBP and 24-h BP by both high-dose and low-dose combination therapy were significantly greater than OLM 20 mg or AZL 16 mg monotherapy. The target BP in the guidelines for management of hypertension is o140/90 mm Hg in the United States and Europe. 2, 4 In Japan, it is o130/85 mm Hg in young/middle-aged patients and o140/ 90 mm Hg in the elderly. 5 In many cases, antihypertensive treatment to achieve the BP goal requires the concomitant use of two or more drugs with different mechanisms of action. As this study confirmed that O/A combination therapy showed the higher rates of achievement of target SeBP than each monotherapy, it would be useful for more strict BP control.
Twenty-four-hour ambulatory BP has been shown to be more closely correlated with the severity of organ damage compared with clinic BP. 14 ABPM is a reliable method for evaluating the 24-h effects of antihypertensive drugs and is suitable for evaluating the effects of once-a-day antihypertensive drugs. The BP in the O/A combination groups was well controlled for 24 h in this study. This shows that O/A combination therapy is capable of strict BP control that persists for 24 h.
Both OLM and AZL originated in Japan and have been developed as a more effective antihypertensive ARB than other ARBs and a longacting dihydropyridine CCB, respectively. 15, 16 In addition to reducing BP, OLM is reported to have the following effects: inhibition of vascular remodeling, anti-inflammatory effect, antiatherosclerotic effect, maintaining cerebral blood flow and prevention of microalbuminuria. [17] [18] [19] [20] AZL is also reported to have the following effects: antioxidative effect, antiatherosclerotic effect, maintaining cerebral blood flow, prevention of proteinuria and PR reduction which is not observed with amlodipine. [21] [22] [23] [24] [25] Furthermore, combined use of ARB and AZL is reported to prevent microalbuminuria in diabetic nephropathy patients. 26 A nonclinical study demonstrated that OLM plus CCB combination showed the various preventive effects on vascular injury depending on which CCB was used; AZL was the most effective CCB tested. 27 In addition, O/A combination has been reported to have an antiatherosclerotic effect and an inhibitory effect on ischemic brain damage in nonclinical studies. 28, 29 These reports suggest that combination of O/A is not only highly effective in reducing BP, but may also protect organs. The COLM study, currently being conducted in Japan, will compare the effects of combination of OLM plus a low-dose diuretic with those of OLM plus a CCB in preventing cardiovascular events in high-risk elderly hypertensive patients. 30 The incidence of AEs in the O/A combination groups was similar to that of the monotherapy groups, and the combination therapy showed a potent antihypertensive effect without an increase in the incidence of AEs. In the elderly (X65 years of age), the incidence of AEs in the O/A combination groups was similar to that in younger individuals, and safety risk was not increased. The incidence of AEs possibly caused by excessive reduction in BP (dizziness, postural dizziness or orthostatic hypotension) was not increased by O/A combination compared with monotherapy. The mean PR in the O/A group showed little change throughout the study, and actually, it tended to decrease. This suggests that the combination of O/A exerts a potent antihypertensive effect without reflex tachycardia. Thus, combination therapy with O/A is well tolerated and considered safe.
We concluded that O/A combination therapy was well tolerated in patients with essential hypertension, and the antihypertensive effect was greater than that of OLM or AZL monotherapy. This ARB/CCB combination of O/A, therefore, could be a useful treatment option for essential hypertension.
